

# ProMed Pharma Announces Acquisition of Manufacturing Facility from Bora Pharmaceuticals

PLYMOUTH, MN, UNITED STATES, August 19, 2025 /EINPresswire.com/ -- ProMed Pharma LLC, a leading provider of polymer-based drug delivery solutions, today announced the acquisition of a 28,000 square foot, state-of-the-art pharmaceutical manufacturing facility located at 2200 N Niagara Lane, Plymouth, Minnesota. The facility was previously owned and operated by Bora

Pharmaceuticals, a global contract development and manufacturing organization.



The acquisition of this facility marks a significant milestone in our growth strategy"

*Clint Schneider*

This strategic acquisition expands ProMed Pharma's footprint and enhances its commercial manufacturing capabilities in complex drug delivery systems, enabling the company to better serve its growing base of pharmaceutical and biotech partners.

"The acquisition of this facility marks a significant milestone in our growth strategy," said Clint Schneider, President of ProMed Pharma. "It not only increases our production capacity but also strengthens our position as a trusted CDMO partner in the development and manufacture of controlled release and combination drug-device products."

The newly acquired facility offers advanced infrastructure for GMP-compliant production, including controlled warehousing, Grade C and D manufacturing space, room for expansion, and capabilities that complement ProMed Pharma's existing operations. The facility is expected to be fully operational by mid-2026.

## About ProMed Pharma

ProMed Pharma partners with pharmaceutical and biotech companies to develop and manufacture drug-releasing implants, combination devices, and other polymer-based dosage forms. Leveraging deep expertise in drug formulation, polymer processing, and medical-grade manufacturing, ProMed delivers integrated solutions for controlled release therapies.

For more information, visit [www.promedpharmallc.com](http://www.promedpharmallc.com).

Promed Pharma

+1 763-331-3800

[email us here](#)

Visit us on social media:

[LinkedIn](#)

---

This press release can be viewed online at: <https://www.einpresswire.com/article/840961031>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2025 Newsmatics Inc. All Right Reserved.